Kymera Therapeutics, Inc. (KYMR)
NASDAQ: KYMR · Real-Time Price · USD
32.17
+2.10 (6.98%)
At close: May 12, 2025, 4:00 PM
32.05
-0.12 (-0.37%)
After-hours: May 12, 2025, 4:09 PM EDT
Kymera Therapeutics Stock Forecast
Stock Price Forecast
The 14 analysts with 12-month price forecasts for Kymera Therapeutics stock have an average target of 55.79, with a low estimate of 36 and a high estimate of 74. The average target predicts an increase of 73.42% from the current stock price of 32.17.
Analyst Consensus: Buy
Analyst Ratings
The average analyst rating for Kymera Therapeutics stock from 14 stock analysts is "Buy". This means that analysts believe this stock is likely to outperform the market over the next twelve months.
Recommendation Trends
| Rating | Dec '24 | Jan '25 | Feb '25 | Mar '25 | Apr '25 | May '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 5 | 5 | 4 | 5 | 5 | 5 |
| Buy | 7 | 7 | 5 | 5 | 5 | 5 |
| Hold | 4 | 3 | 3 | 3 | 3 | 4 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 16 | 15 | 12 | 13 | 13 | 14 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Guggenheim | Guggenheim | Strong Buy Reiterates $52 | Strong Buy | Reiterates | $52 | +61.64% | May 12, 2025 |
| B of A Securities | B of A Securities | Hold Maintains $47 → $44 | Hold | Maintains | $47 → $44 | +36.77% | May 12, 2025 |
| Citigroup | Citigroup | Strong Buy Initiates $52 | Strong Buy | Initiates | $52 | +61.64% | Mar 13, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $54 → $60 | Strong Buy | Maintains | $54 → $60 | +86.51% | Feb 28, 2025 |
| Stephens & Co. | Stephens & Co. | Buy Reiterates $60 | Buy | Reiterates | $60 | +86.51% | Jan 21, 2025 |
Financial Forecast
Revenue This Year
54.72M
from 47.07M
Increased by 16.24%
Revenue Next Year
66.98M
from 54.72M
Increased by 22.41%
EPS This Year
-3.77
from -2.98
EPS Next Year
-4.15
from -3.77
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 131.9M | 157.3M | 245.7M | ||
| Avg | 54.7M | 67.0M | 87.8M | ||
| Low | 13.3M | n/a | -37.2M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 180.2% | 187.5% | 266.9% | ||
| Avg | 16.2% | 22.4% | 31.1% | ||
| Low | -71.7% | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -2.74 | -3.27 | -2.86 | ||
| Avg | -3.77 | -4.15 | -4.17 | ||
| Low | -4.63 | -5.87 | -7.58 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.